These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 29341370

  • 21. Metabolic outcomes of matched patient populations initiating exenatide BID vs. insulin glargine in an ambulatory care setting.
    Pawaskar M, Li Q, Hoogwerf BJ, Reynolds MW, Faries D, Engelman W, Bruhn D, Bergenstal RM.
    Diabetes Obes Metab; 2012 Jul; 14(7):626-33. PubMed ID: 22321776
    [Abstract] [Full Text] [Related]

  • 22. Determining predictors of response to exenatide in type 2 diabetes.
    Anderson SL, Trujillo JM, McDermott M, Saseen JJ.
    J Am Pharm Assoc (2003); 2012 Jul; 52(4):466-71. PubMed ID: 22825226
    [Abstract] [Full Text] [Related]

  • 23. Effectiveness and safety of exenatide in Korean patients with type 2 diabetes inadequately controlled with oral hypoglycemic agents: an observational study in a real clinical practice.
    Hwang YC, Kim A, Jo E, Yang Y, Cho JH, Lee BW.
    BMC Endocr Disord; 2017 Oct 25; 17(1):68. PubMed ID: 29065865
    [Abstract] [Full Text] [Related]

  • 24. Exenatide Once Weekly: Effectiveness, Tolerability, and Discontinuation Predictors in a Real-world Setting.
    Di Dalmazi G, Coluzzi S, Baldassarre MPA, Sorbo SE, Dell'Aquila S, Febo F, Ginestra F, Graziano G, Rossi MC, Consoli A, Formoso G.
    Clin Ther; 2020 Sep 25; 42(9):1738-1749.e1. PubMed ID: 32753164
    [Abstract] [Full Text] [Related]

  • 25. [Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide].
    Pujante Alarcón P, Hellín Gil MD, Román LM, Ferrer Gómez M, García Zafra MV, Tébar Massó J.
    Med Clin (Barc); 2012 Dec 01; 139(13):572-8. PubMed ID: 22209597
    [Abstract] [Full Text] [Related]

  • 26. [Effects of exenatide lar in type 2 diabetes mellitus and obesity].
    Sierra Poyatos R, Riobó Serván P, Vázquez Martínez C.
    Nutr Hosp; 2014 Oct 24; 31(1):292-8. PubMed ID: 25561121
    [Abstract] [Full Text] [Related]

  • 27. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus.
    Ratner RE, Maggs D, Nielsen LL, Stonehouse AH, Poon T, Zhang B, Bicsak TA, Brodows RG, Kim DD.
    Diabetes Obes Metab; 2006 Jul 24; 8(4):419-28. PubMed ID: 16776749
    [Abstract] [Full Text] [Related]

  • 28. Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients.
    Montvida O, Klein K, Kumar S, Khunti K, Paul SK.
    Diabetes Obes Metab; 2017 Jan 24; 19(1):108-117. PubMed ID: 27629433
    [Abstract] [Full Text] [Related]

  • 29. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.
    Health Technol Assess; 2010 Jul 24; 14(36):1-248. PubMed ID: 20646668
    [Abstract] [Full Text] [Related]

  • 30. Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes.
    Blonde L, Pencek R, MacConell L.
    Cardiovasc Diabetol; 2015 Feb 03; 14():12. PubMed ID: 25645567
    [Abstract] [Full Text] [Related]

  • 31. One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice.
    Buysschaert M, Preumont V, Oriot PR, Paris I, Ponchon M, Scarnière D, Selvais P, UCL Study Group for Exenatide.
    Diabetes Metab; 2010 Nov 03; 36(5):381-8. PubMed ID: 20598606
    [Abstract] [Full Text] [Related]

  • 32. Effects of HbA1c and weight reduction on blood pressure in patients with type 2 diabetes mellitus treated with exenatide*.
    Paul S, Best J, Klein K, Han J, Maggs D.
    Diabetes Obes Metab; 2012 Sep 03; 14(9):826-34. PubMed ID: 22510305
    [Abstract] [Full Text] [Related]

  • 33. Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.
    Gadde KM, Vetter ML, Iqbal N, Hardy E, Öhman P, DURATION-NEO-2 study investigators.
    Diabetes Obes Metab; 2017 Jul 03; 19(7):979-988. PubMed ID: 28205322
    [Abstract] [Full Text] [Related]

  • 34. Durability of effects of exenatide treatment on glycemic control, body weight, systolic blood pressure, C-reactive protein, and triglyceride concentrations.
    Varanasi A, Chaudhuri A, Dhindsa S, Arora A, Lohano T, Vora MR, Dandona P.
    Endocr Pract; 2011 Jul 03; 17(2):192-200. PubMed ID: 20841306
    [Abstract] [Full Text] [Related]

  • 35. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
    Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.
    Clin Ther; 2008 Aug 03; 30(8):1448-60. PubMed ID: 18803987
    [Abstract] [Full Text] [Related]

  • 36. Early Pharmacodynamic Effects of Exenatide Once Weekly in Type 2 Diabetes Are Independent of Weight Loss: A Pooled Analysis of Patient-level Data.
    Trautmann ME, Han J, Ruggles J.
    Clin Ther; 2016 Jun 03; 38(6):1464-1473. PubMed ID: 27126504
    [Abstract] [Full Text] [Related]

  • 37. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
    Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, Taylor K.
    Diabetes Care; 2007 Jun 03; 30(6):1487-93. PubMed ID: 17353504
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database.
    Horton ES, Silberman C, Davis KL, Berria R.
    Diabetes Care; 2010 Aug 03; 33(8):1759-65. PubMed ID: 20460445
    [Abstract] [Full Text] [Related]

  • 40. Exenatide once-weekly clinical development: safety and efficacy across a range of background therapies.
    Stonehouse A, Walsh B, Cuddihy R.
    Diabetes Technol Ther; 2011 Oct 03; 13(10):1063-9. PubMed ID: 21732798
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.